CCA - Imaging and biomarkers

Research output

Research output per year 1981 2018 2019 2021 2022 2023 2024

• 4233 Article
• 445 Review article
• 234 Comment/Letter to the editor
• 222 Meeting Abstract
• 630 More
  • 158 Chapter
  • 153 Phd-Thesis - Research and graduation internal
  • 105 Conference contribution
  • 72 Letter
  • 54 Editorial
  • 18 Erratum/Corrigendum
  • 17 Poster
  • 14 Paper
  • 9 Abstract
  • 7 Book
  • 7 Short survey
  • 4 Report
  • 4 Patent
  • 3 Inaugural speech
  • 3 Phd-Thesis - Research and graduation external
  • 1 Book editing
  • 1 Phd-Thesis - Research internal and graduation external

Research output per year

Research output per year

Search results

• 2023

  Natural speech as a digital biomarker in preclinical Alzheimer’s disease: Usability and reliability of a remote burst speech assessment

  van den Berg, R. L., de Boer, C., Zwan, M. D., Robin, J., Simpson, B., Harrison, J. E., Jutten, R. J., Dubbelman, M. A., Barkhof, F., Collij, L. E., van Harten, A. C., Mank, A., Kroeze, L. A., Teunissen, C. E., van der Flier, W. M. & Sikkes, S. A. M., 17 Jul 2023.

  Research output: Contribution to conference › Poster › Academic
• 2020

  89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck.

  Voortman, J., 2020.

  Research output: Contribution to conference › Poster › Academic

  Open Access

• Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study.

  Voortman, J., 2020.

  Research output: Contribution to conference › Poster › Academic

  Open Access

• Early response marker during pembrolizumab treatment in metastatic urothelial cancer: Temporal shift in peripheral CD4 T cells expressing chemokine receptors.

  Voortman, J., 2020.

  Research output: Contribution to conference › Poster › Academic

  Open Access

• PO-0996: Early mortality in stage III NSCLC after radical non-surgical therapy following ESMO guidelines

  Ronden-Kianoush, M., de Vries, I. F. R., Bahce, I., De Haan, P. F., Tiemessen, M. A., Spoelstra, F. O. B., Van Diepen, V. D. M., Haasbeek, C. J. A., Tarasevych, S., Daniels, H. J. M. A., Dahele, M. R., Hashemi, S. M., Becker, A., Veltman, J. D., Crombag, L. M. M., Senan, S. & Verbakel, W. F. A. R., 2020, p. S531-S532.

  Research output: Contribution to conference › Poster › Academic
• 2019

  Pursuit of an international language of glioma research: common data elements for the longitudinal study of adult malignant glioma

  Kouwenhoven, MCM., 2019, (Accepted/In press).

  Research output: Contribution to conference › Poster › Academic
• 2018

  NLSEV2018-P21 - EV-derived microRNA profiles from patients with classical Hodgkin Lymphoma can discriminate between active disease and complete response

  Voortman, J., 2018.

  Research output: Contribution to conference › Poster › Academic

• Understanding cognitive functioning in diffuse glioma patients: the relevance of IDH mutation status and functional connectivity

  Douw, L., 18 Sept 2018.

  Research output: Contribution to conference › Poster › Academic
• 2017

  2964 - Comparison of carboplatin with 5-fluorouracil (carbo-5FU) versus cisplatin as concomitant chemoradiotherapy (CRT) for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)

  Voortman, J., 10 Sept 2017.

  Research output: Contribution to conference › Poster › Academic

• A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.

  Voortman, J., 2017.

  Research output: Contribution to conference › Poster › Academic

  Open Access

• Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma. .

  Meijer, LL., Giovannetti, E., Le Large, TYS. & Kazemier, G., 2017.

  Research output: Contribution to conference › Poster › Academic

• iHIPEC: advanced imaging in HIPEC patients.

  Sluiter, NR., Tuynman, JB., Vlek, SL., Brandsma, HT., Wijsmuller, AR. & van Grieken, NCT., 2017.

  Research output: Contribution to conference › Poster › Academic
• 2016

  S471 SKELETAL MUSCLE MASS MEASUREMENTS AND ASSOCIATION WITH TREATMENT OUTCOME IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CANCER TREATED WITH CONCURRENT CHEMORADIOTHERAPY

  Voortman, J., 2016.

  Research output: Contribution to conference › Poster › Academic
• 2014

  A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).

  Voortman, J., 2014.

  Research output: Contribution to conference › Poster › Academic

  Open Access
• 2011

  Array-based comparative genomic hybridization analysis to identify prognostic markers for resected pancreatic cancer.

  Voortman, J., 2011.

  Research output: Contribution to conference › Poster › Academic
• 2010

  Abstract 2995: MicroRNA expression and outcome of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program (IALT-Bio)

  Voortman, J., 2010.

  Research output: Contribution to conference › Poster › Academic

  Open Access

• Abstract 3000: MicroRNA-21 as a biomarker for benefit from adjuvant therapy in resectable pancreatic adenocarcinoma

  Voortman, J., 2010.

  Research output: Contribution to conference › Poster › Academic

  Open Access